Tenaya Therapeutics $207 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the initial public offering of 13,800,000 shares of common stock of Tenaya Therapeutics, Inc. at $15.00 per share (which includes the exercise in full by the underwriters of their over-allotment option), for total gross proceeds of $207 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “TNYA.”
Based in South San Francisco, California, Tenaya Therapeutics is a biotechnology company that discovers, develops and delivers curative therapies to address the underlying drivers of heart disease. Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.
The Davis Polk corporate team included partner Alan F. Denenberg and associate Alex DeGroat. The intellectual property and technology transactions team included partner David R. Bauer and associates Mikaela Dealissia, Chelsea Renter and David A. Frey. The tax team included partner Mario J. Verdolini. Associate Sijia Cai provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.